Previous 10 | Next 10 |
2023-04-27 15:49:00 ET Shares of the non-viral liver disease specialist Intercept Pharmaceuticals (NASDAQ: ICPT) are under heavy pressure today. Specifically, the drugmaker's stock was down by 9.7% on exceptionally high volume as of 3:02 p.m. ET Thursday afternoon. The big loss ...
2023-04-27 14:24:02 ET Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Conference Call April 27, 2023, 8:00 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and Chief Executive Officer Dr. Michell...
2023-04-27 13:52:44 ET For further details see: Intercept Pharma off 11% on Q1 misses
2023-04-27 10:01:57 ET Gainers: ContraFect ( CFRX ) +112% . Accuray ( ARAY ) +14% . Mainz Biomed ( MYNZ ) +15% . Mangoceuticals ( MGRX ) +14% . Immix Biopharma ( IMMX ) +9% . Losers: Baudax Bio ( BXRX ) -52% ....
2023-04-27 07:08:21 ET Intercept Pharma press release ( NASDAQ: ICPT ): Q1 GAAP EPS of -$0.77 misses by $0.15 . Revenue of $68M (+14.9% Y/Y) misses by $4.68M . For further details see: Intercept Pharma GAAP EPS of -$0.77 misses by $0.15, revenue of $68M m...
Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting set for May 19, 2023, to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH; PDUFA Target Action Date ...
Seven abstracts in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) accepted at EASL 2023 Accepted abstracts include podium presentation of new data from the planned interim analysis of a Phase 2 study of investigational combination of obeticholic ac...
2023-04-26 12:02:15 ET Intercept Pharma ( NASDAQ: ICPT ) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open. The consensus EPS Estimate is -$0.60 (-3.4% Y/Y) and the consensus Revenue Estimate is $72.68M (-17.9% Y/Y). Over the last...
2023-04-25 13:50:22 ET Summary Obeticholic acid (OCA) has shown potential for treating NASH with fibrosis, demonstrating improvements in liver histology, inflammation, and steatosis. Safety concerns, including liver injury and worsening cardiometabolic risk factors, raise doubts a...
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financia...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...